Early prediction of cardiac allograft vasculopathy and heart transplant failure

Carlos A. Labarrere, J. R. Woods, J. W. Hardin, G. L. Campana, M. A. Ortiz, B. R. Jaeger, B. Reichart, Jose Bonnin, A. Currin, S. Cosgrove, D. E. Pitts, P. C. Kirlin, Jacqueline O'Donnell, D. A. Hormuth, T. C. Wozniak

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Early risk-prediction is essential to prevent cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients. We developed multivariate models to identify patients likely to experience CAV, severe CAV, and failure due to CAV, at 1, 5 and 10 years. A cohort of 172 patients was followed prospectively for 6.7 ± 3.9 years. Logistic regression models were developed and cross-validated using bootstrap resampling. Predictive markers of atherothrombosis (myocardial fibrin deposition, and loss of vascular antithrombin and tissue plasminogen activator) and arterial endothelial activation (intercellular adhesion molecule-1 expression) were measured in serial biopsies obtained within 3 months posttransplant. Most markers were univariately associated with outcome. Multivariate models showed that loss of tissue plasminogen activator was the dominant and, in most cases, only predictor of long-term CAV (p < 0.001), severe CAV (p < 0.001), and graft failure due to CAV (p < 0.001). The models discriminated patients having adverse outcomes, had particularly high negative predictive values (graft failure due to CAV: 99%, 99% and 95% at 1, 5 and 10 years) and predicted event incidence and time to event. Early absence of atherothrombotic risk identifies a patient subgroup that rarely develops CAV or graft failure, implying that this low-risk subgroup could possibly be followed with fewer invasive procedures.

Original languageEnglish
Pages (from-to)528-535
Number of pages8
JournalAmerican Journal of Transplantation
Volume11
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Allografts
Heart Failure
Transplants
Tissue Plasminogen Activator
Logistic Models
Antithrombins
Intercellular Adhesion Molecule-1
Fibrin
Blood Vessels
Biopsy
Incidence

Keywords

  • Cardiac allograft vasculopathy
  • Endomyocardial biopsy
  • Graft failure
  • Heart transplantation
  • Immunopathology
  • Long-term outcomes
  • Microvascular thrombosis
  • Prediction models
  • Risk markers

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Labarrere, C. A., Woods, J. R., Hardin, J. W., Campana, G. L., Ortiz, M. A., Jaeger, B. R., ... Wozniak, T. C. (2011). Early prediction of cardiac allograft vasculopathy and heart transplant failure. American Journal of Transplantation, 11(3), 528-535. https://doi.org/10.1111/j.1600-6143.2010.03401.x

Early prediction of cardiac allograft vasculopathy and heart transplant failure. / Labarrere, Carlos A.; Woods, J. R.; Hardin, J. W.; Campana, G. L.; Ortiz, M. A.; Jaeger, B. R.; Reichart, B.; Bonnin, Jose; Currin, A.; Cosgrove, S.; Pitts, D. E.; Kirlin, P. C.; O'Donnell, Jacqueline; Hormuth, D. A.; Wozniak, T. C.

In: American Journal of Transplantation, Vol. 11, No. 3, 03.2011, p. 528-535.

Research output: Contribution to journalArticle

Labarrere, CA, Woods, JR, Hardin, JW, Campana, GL, Ortiz, MA, Jaeger, BR, Reichart, B, Bonnin, J, Currin, A, Cosgrove, S, Pitts, DE, Kirlin, PC, O'Donnell, J, Hormuth, DA & Wozniak, TC 2011, 'Early prediction of cardiac allograft vasculopathy and heart transplant failure', American Journal of Transplantation, vol. 11, no. 3, pp. 528-535. https://doi.org/10.1111/j.1600-6143.2010.03401.x
Labarrere, Carlos A. ; Woods, J. R. ; Hardin, J. W. ; Campana, G. L. ; Ortiz, M. A. ; Jaeger, B. R. ; Reichart, B. ; Bonnin, Jose ; Currin, A. ; Cosgrove, S. ; Pitts, D. E. ; Kirlin, P. C. ; O'Donnell, Jacqueline ; Hormuth, D. A. ; Wozniak, T. C. / Early prediction of cardiac allograft vasculopathy and heart transplant failure. In: American Journal of Transplantation. 2011 ; Vol. 11, No. 3. pp. 528-535.
@article{f1d5ecdf49404fd7855688fe61e45036,
title = "Early prediction of cardiac allograft vasculopathy and heart transplant failure",
abstract = "Early risk-prediction is essential to prevent cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients. We developed multivariate models to identify patients likely to experience CAV, severe CAV, and failure due to CAV, at 1, 5 and 10 years. A cohort of 172 patients was followed prospectively for 6.7 ± 3.9 years. Logistic regression models were developed and cross-validated using bootstrap resampling. Predictive markers of atherothrombosis (myocardial fibrin deposition, and loss of vascular antithrombin and tissue plasminogen activator) and arterial endothelial activation (intercellular adhesion molecule-1 expression) were measured in serial biopsies obtained within 3 months posttransplant. Most markers were univariately associated with outcome. Multivariate models showed that loss of tissue plasminogen activator was the dominant and, in most cases, only predictor of long-term CAV (p < 0.001), severe CAV (p < 0.001), and graft failure due to CAV (p < 0.001). The models discriminated patients having adverse outcomes, had particularly high negative predictive values (graft failure due to CAV: 99{\%}, 99{\%} and 95{\%} at 1, 5 and 10 years) and predicted event incidence and time to event. Early absence of atherothrombotic risk identifies a patient subgroup that rarely develops CAV or graft failure, implying that this low-risk subgroup could possibly be followed with fewer invasive procedures.",
keywords = "Cardiac allograft vasculopathy, Endomyocardial biopsy, Graft failure, Heart transplantation, Immunopathology, Long-term outcomes, Microvascular thrombosis, Prediction models, Risk markers",
author = "Labarrere, {Carlos A.} and Woods, {J. R.} and Hardin, {J. W.} and Campana, {G. L.} and Ortiz, {M. A.} and Jaeger, {B. R.} and B. Reichart and Jose Bonnin and A. Currin and S. Cosgrove and Pitts, {D. E.} and Kirlin, {P. C.} and Jacqueline O'Donnell and Hormuth, {D. A.} and Wozniak, {T. C.}",
year = "2011",
month = "3",
doi = "10.1111/j.1600-6143.2010.03401.x",
language = "English",
volume = "11",
pages = "528--535",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Early prediction of cardiac allograft vasculopathy and heart transplant failure

AU - Labarrere, Carlos A.

AU - Woods, J. R.

AU - Hardin, J. W.

AU - Campana, G. L.

AU - Ortiz, M. A.

AU - Jaeger, B. R.

AU - Reichart, B.

AU - Bonnin, Jose

AU - Currin, A.

AU - Cosgrove, S.

AU - Pitts, D. E.

AU - Kirlin, P. C.

AU - O'Donnell, Jacqueline

AU - Hormuth, D. A.

AU - Wozniak, T. C.

PY - 2011/3

Y1 - 2011/3

N2 - Early risk-prediction is essential to prevent cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients. We developed multivariate models to identify patients likely to experience CAV, severe CAV, and failure due to CAV, at 1, 5 and 10 years. A cohort of 172 patients was followed prospectively for 6.7 ± 3.9 years. Logistic regression models were developed and cross-validated using bootstrap resampling. Predictive markers of atherothrombosis (myocardial fibrin deposition, and loss of vascular antithrombin and tissue plasminogen activator) and arterial endothelial activation (intercellular adhesion molecule-1 expression) were measured in serial biopsies obtained within 3 months posttransplant. Most markers were univariately associated with outcome. Multivariate models showed that loss of tissue plasminogen activator was the dominant and, in most cases, only predictor of long-term CAV (p < 0.001), severe CAV (p < 0.001), and graft failure due to CAV (p < 0.001). The models discriminated patients having adverse outcomes, had particularly high negative predictive values (graft failure due to CAV: 99%, 99% and 95% at 1, 5 and 10 years) and predicted event incidence and time to event. Early absence of atherothrombotic risk identifies a patient subgroup that rarely develops CAV or graft failure, implying that this low-risk subgroup could possibly be followed with fewer invasive procedures.

AB - Early risk-prediction is essential to prevent cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients. We developed multivariate models to identify patients likely to experience CAV, severe CAV, and failure due to CAV, at 1, 5 and 10 years. A cohort of 172 patients was followed prospectively for 6.7 ± 3.9 years. Logistic regression models were developed and cross-validated using bootstrap resampling. Predictive markers of atherothrombosis (myocardial fibrin deposition, and loss of vascular antithrombin and tissue plasminogen activator) and arterial endothelial activation (intercellular adhesion molecule-1 expression) were measured in serial biopsies obtained within 3 months posttransplant. Most markers were univariately associated with outcome. Multivariate models showed that loss of tissue plasminogen activator was the dominant and, in most cases, only predictor of long-term CAV (p < 0.001), severe CAV (p < 0.001), and graft failure due to CAV (p < 0.001). The models discriminated patients having adverse outcomes, had particularly high negative predictive values (graft failure due to CAV: 99%, 99% and 95% at 1, 5 and 10 years) and predicted event incidence and time to event. Early absence of atherothrombotic risk identifies a patient subgroup that rarely develops CAV or graft failure, implying that this low-risk subgroup could possibly be followed with fewer invasive procedures.

KW - Cardiac allograft vasculopathy

KW - Endomyocardial biopsy

KW - Graft failure

KW - Heart transplantation

KW - Immunopathology

KW - Long-term outcomes

KW - Microvascular thrombosis

KW - Prediction models

KW - Risk markers

UR - http://www.scopus.com/inward/record.url?scp=79951989641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951989641&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2010.03401.x

DO - 10.1111/j.1600-6143.2010.03401.x

M3 - Article

VL - 11

SP - 528

EP - 535

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 3

ER -